Supplier sign in
Home
STAY INFORMED
Subscribe to our monthly newsletter.
Your email address will never be disclosed to any third party.
Read our privacy notice.

     

News

Post your news
Alfa Chemistry Testing Lab Releases Nano-products Safety Evaluation Service
Alfa Chemistry Testing Lab Releases Nano-products Safety Evaluation Service
Earlier this month in May, 2020, Alfa Chemistry Testing Lab, a professional testing and analysis organization, announced to have released nano-products safety evaluation services for companies and agencies that are engaged with the development and application of nano-products. Nanomaterials exhibit unique physical and chemical properties in contrast with engineered materials. As more nanotechnology products have moved into the marketplace, especially in the public health-related areas such as food, cosmetics or drug, there is a growing need to assess the potential risks that exposure to nanomaterials might bring to human health and the environment. “Considering this, we decide to offer a wide range of safety evaluation services for nano-products at biological level, cellular level, molecular level and environmental level,” says a senior scientist from Alfa Chemistry Testing Lab. Characterization of nanomaterials Physical-chemical characterization of nanomaterials
28-05-2020  |  019x  |  Product news  | 
Alfa Chemistry Offers PEG linkers for the Science Community
Alfa Chemistry Offers PEG linkers for the Science Community
Earlier this month in May, 2020, the world’s leading chemical supplier Alfa Chemistry announced that a total of close to 800 PEG linker products are now available for its customers worldwide, including acid PEG linkers, alkyl PEG linkers, amino PEG linkers, azido PEG linkers, benzyl PEG linkers, biotin PEG linkers, fmoc PEG linkers, NHBoc PEG linkers, NHS ester PEG linkers, t-butyl ester PEG linkers, Thp peg linkers, and other PEG Linkers. Polyethylene glycol (PEG) linkers are necessary for bioconjugation and pegylation. Due to their characteristics of water solubility, lack of toxicity, low immunogenicity, well defined chain lengths and molecular weights, PEG linkers are widely used in pharmaceutical and biotechnology applications. PEGylation is considered one of the most successful techniques to enhance the therapeutic and biotechnological potential of molecules, such as therapeutic peptides, proteins, small molecules, oligonucleotides, and antibodies. The PEG based
27-05-2020  |  027x  |  Product news  | 
AI & Medicine—An Expert in AI-aided Drug Discovery and Medical Application
AI & Medicine—An Expert in AI-aided Drug Discovery and Medical Application
Recently founded, the New York-based company AI & Medicine is an expert in the field of AI-Powered drug discovery, personalized healthcare and various medical applications. Having launched a unique AI-aided drug discovery platform last month, this company grows quickly with concerted support from many talented researchers and scientists. It offers drug R & D solutions from the perspective of AI for medical institutions and pharmaceutical enterprises worldwide. AI is transforming the practice of medicine. Owing to its ability to identify meaningful relationships in raw data, AI can be used in multiple medical scenarios. For example, it helps doctors diagnose patients more accurately, make predictions about patients’ future health, and even recommend better treatments. It is quite fair to say that AI can be applied in nearly every field of medicine. AI & Medicine can help apply machine learning to solve the following four concrete problems: Drug Research and Development
27-05-2020  |  024x  |  Industry news  | 
Circular economy and the Corona crisis
Circular economy and the Corona crisis
The Corona crisis forces us to reflect. The likely long break in our society necessitates unprecedented interventions and changes. This situation may well be crucial for the transition to a circular economy. LabMakelaar Benelux B.V. has been committed to a circular economy for many years. With the purchase and sale of high-quality second-hand lab equipment, furniture and consumables, we help other companies to also promote the circular economy and to do business in a socially responsible manner. We do this with LabMakelaar.com and Laboratorium.shop. Since November last year we have also added LabForRent. LabForRent.nl is a platform that helps prevent the vacancy of valuable lab space and production facilities. In the Benelux there is a clear overcapacity. In the context of the circular economy, it is important that these vacant spaces are filled with start-ups, for example. Because of these three branches within LabMakelaar Benelux B.V. we can offer a total package
25-05-2020  |  100x  |  Industry news  | 
Sell your old/ used LC-MS Systems to Labrecycling Are there any surplus LC-MS Systems dusting in your warehouse or in the corner of your laboratory?
Sell your old/ used LC-MS Systems to Labrecycling
Are there any surplus LC-MS Systems dusting in your warehouse or in the corner of your laboratory? Currently Labrecycling is searching for LC-MS systems and is asking for your help. We search among other things: •Agilent 6420/ 6460/ 6470/ 6490 and 6495 •Shimadzu LC-MS 8040/ LC-MS 8050 •Thermo Q Exactive •Thermo TSQ Vantage •Waters Xevo G2 XS Qtof Labrecycling recycles chromatographic instruments and has room to take over your equipment. Throwing away is a sin. Make your warehouse clear and give your LC-MS a 2nd life.
25-05-2020  |  044x  |  Product news  | 
Huateng Pharma Develpoed Kinds Of Intermediates For Carfilzomib
Huateng Pharma Develpoed Kinds Of Intermediates For Carfilzomib
Carfilzomib (marketed under the trade name Kyprolis, developed by Onyx Pharmaceuticals) is an anti-cancer drug acting as a selective proteasome inhibitor. Chemically, it is a tetrapeptide epoxyketone and an analog of epoxomicin. Carfilzomib is derived from epoxomicin, a natural product that was shown by the laboratory of Craig Crews at Yale University to inhibit the proteasome. The Crews laboratory subsequently invented a more specific derivative of epoxomicin named YU101, which was licensed to Proteolix, Inc. Scientists at Proteolix invented a new, distinct compound that had potential use as a drug in humans, known as carfilzomib. Proteolix advanced carfilzomib to multiple Phase 1 and 2 clinical trials, including a pivotal phase 2 clinical trial designed to seek accelerated approval. Clinical trials for carfilzomib continue under Onyx Pharmaceuticals, which acquired Proteolix in 2009. Carfilzomib covalently irreversibly binds to and inhibits the chymotrypsin-like
25-05-2020  |  033x  |  Product news  | 
Following 6 items
ARCHIVE
MAY
2020
APR
2020
MAR
2020
FEB
2020
JAN
2020
DEC
2019
NOV
2019
OCT
2019
SEPT
2019
AUG
2019
JULY
2019
JUNE
2019
MAXUS MEDIA
LABinsights.net LABinsights.de LABinsights.nl
SIGN UP FOR OUR NEWSLETTER
Newsletter archive
Service and contact
ContactDisclaimerPrivacyAdvertising